Windtree Therapeutics, a Nasdaq-listed biotech firm, plans to purchase up to $700 million worth of BNB, the fifth-largest cryptocurrency, following its recent all-time high. The company is raising $520 million through an equity line of credit and a stock-purchase agreement to facilitate these investments, previously announcing a plan to acquire $200 million in BNB. Partnering with crypto exchange Kraken for asset custody, Windtree aims to enhance its balance sheet with digital assets. CEO Jed Latkin emphasized the importance of stockholder approval for these purchases. BNB, with a market cap of $106.9 billion, peaked at $808 but has seen a slight decline. Windtree's strategy mirrors that of other firms like Strategy, which have also begun accumulating various cryptocurrencies to bolster their stock performance. The company observed a significant increase in its stock over the past month, despite a recent dip. This trend of corporations investing in cryptocurrencies is becoming more common, as seen with companies like Nano Labs and Strategy.

Source đź”—